Mayo Clinic Laboratory and Pathology Research Roundup: Aug. 13

By Kelley Luedke • August 13, 2018

Share this:

The Research Roundup provides an overview of the past week’s research from Mayo Medical Laboratories consultants, including featured abstracts and complete list of published studies and reviews.

Featured Abstract

Diagnostic Thresholds for Androgen-Producing Tumors or Pathologic Hyperandrogenism in Women by Use of Total Testosterone Concentrations Measured by Liquid Chromatography-Mass Spectrometry

Previously defined thresholds for total testosterone (TT) concentrations to screen for androgen-producing tumors (APTs) have used RIA, which can be less accurate in women. Mayo Clinic researchers aimed to define diagnostic thresholds to screen for APTs or postmenopausal pathologic hyperandrogenism using TT concentrations measured by LC-MS/MS. Researchers performed a retrospective cohort study on all women with TT ≥3.5 nmol/L and all postmenopausal women presenting with hyperandrogenism between 2004 and 2014 at Mayo Clinic in Rochester, Minnesota. The diagnostic threshold for TT concentration as measured by LC-MS/MS to identify APT in women with biochemical severe hyperandrogenemia was TT ≥5.1 nmol/L. In postmenopausal women, the diagnostic threshold for pathologic hyperandrogenism was lower (TT ≥2.2 nmol/L). The study was published in Clinical Chesmitry.

Published to PubMed This Week

• • • • • Disseminated Peritoneal Leiomyomatosis After Uterine Artery Embolization
          CardioVascular and Interventional Radiology
        • Selected Giant Cell Rich Lesions of the Temporal Bone
          Head and Neck Pathology
        • 1-h High-Sensitivity Troponin Rule-Out and Rule-In Approach: Strengths and Potential Weaknesses
          Journal of the American College of Cardiology
        • LGI1 and CASPR2 Neurological Autoimmunity in Children
          Annals of Neurology
        • History of Autoimmune Conditions and Lymphoma Prognosis
          Blood Cancer Journal
        • C3 Glomerulopathy: Ten Years' Experience at Mayo Clinic
          Mayo Clinic Proceedings
        • The Clinical Outcomes of Reclassified Erythroleukemia (Erythroid/Myeloid) as Myelodysplastic Syndrome (MDS) Per 2017 WHO Guideline Compared to MDS
          American Journal of Hematology
        • Plasma Cell Proliferative Index Post-Transplant is a Powerful Predictor of Prognosis in Myeloma Patients Failing to Achieve a Complete Response
          Bone Marrow Transplant
        • Antibacterial Activity of Reduced Iron Clay Against Pathogenic Bacteria Associated With Wound Infections
          International Journal of Antimicrobial Agents
        • Clinical Correlation of Cytomegalovirus Infection with CMV-Specific CD8+ T Cell Immune Competence Score and Lymphocyte Subsets in Solid Organ Transplant Recipients
          Transplantation
        • Association Between Renal Cell Carcinoma and Myelodysplastic Syndromes: Epigenetic Underpinning
          Clinical Genitourinary Cancer

Kelley Luedke

Kelley Luedke is a Marketing Channel Manager at Mayo Clinic Laboratories. She is the principle editor and writer of Insights and leads social media and direct marketing strategy. Kelley has worked at Mayo Clinic since 2013. Outside of work, you can find Kelley running, traveling, playing with her kitty, and exploring new foods.